SCHEMBL23124372

SCHEMBL23124372

O=C(N1CCC1)N1CCNCC1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.86
CHKA P35790 1/20 0.86
ALDH1A1 P00352 3/20 0.59
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA9 Q16790 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TP53 P04637 1/20 0.50
CHRNB2 P17787 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48
CHRNB3 Q05901 1/20 0.48
CHRNA6 Q15825 1/20 0.48
SIGMAR1 Q99720 1/20 0.42
HSD11B1 P28845 1/20 0.41
HSP90AA1 P07900 1/20 0.39
POLB P06746 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL937637 0.95 CA2 (0.95) CA2CHKAALDH1A1CA12CA1
SCHEMBL27793589 0.92 CA2 (0.82) CA2CHKAALDH1A1CA12CA1
SCHEMBL3175235 0.92 CA2 (1.00) CA2CHKAALDH1A1CA12CA1
Hydrochloric Acid SCHEMBL23124310 0.92 CA2 (0.91) CA2CHKAALDH1A1CA12CA1
SCHEMBL2561632 0.92 CA2 (0.80) CA2CHKAALDH1A1CA12CA1
Hydrochloric Acid SCHEMBL30493400 0.90 CA2 (0.95) CA2CHKAALDH1A1CA12CA1
Hydrochloric Acid SCHEMBL27001665 0.89 CA2 (0.76) CA2CHKAALDH1A1CA12CA1
SCHEMBL10665698 0.89 CA2 (0.76) CA2CHKAALDH1A1CA12CA1
SCHEMBL27713059 0.89 CA2 (0.76) CA2CHKAALDH1A1CA12CA1
Hydrochloric Acid SCHEMBL27766200 0.89 CA2 (0.76) CA2CHKAALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO LTD (CN) 2025-12-25 US disclosed
EP-4514803-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF Danatlas Pharmaceuticals Co., Ltd. (CN) 2025-03-05 EP disclosed
US-20240140954-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2024-05-02 US disclosed
WO-2023208092-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2023-11-02 WO disclosed
US-20220389003-A1 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-12-08 US disclosed
WO-2021055744-A1 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2021-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389003-A1 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS PARG, PARP11, PARN CA2 1551/4885CHKA 3851/4885ALDH1A1 1124/4885
US-20240140954-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF CYP11B2, SDHA, CYP3A43 CA2 3053/4885CHKA 647/4885ALDH1A1 740/4885
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF CYP4A11, CYP11B1, CYP2D6 CA2 445/4885CHKA 550/4885ALDH1A1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.